ZA200908303B - A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation - Google Patents

A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Info

Publication number
ZA200908303B
ZA200908303B ZA2009/08303A ZA200908303A ZA200908303B ZA 200908303 B ZA200908303 B ZA 200908303B ZA 2009/08303 A ZA2009/08303 A ZA 2009/08303A ZA 200908303 A ZA200908303 A ZA 200908303A ZA 200908303 B ZA200908303 B ZA 200908303B
Authority
ZA
South Africa
Prior art keywords
disorders
treatment
protein aggregation
cyclohexane polyalcohol
polyalcohol formulation
Prior art date
Application number
ZA2009/08303A
Other languages
English (en)
Inventor
Joanne Mclaurin
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Joanne Mclaurin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc, Joanne Mclaurin filed Critical Waratah Pharmaceuticals Inc
Publication of ZA200908303B publication Critical patent/ZA200908303B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2009/08303A 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation ZA200908303B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78052606P 2006-03-09 2006-03-09
US81986406P 2006-07-11 2006-07-11
US89766707P 2007-01-26 2007-01-26

Publications (1)

Publication Number Publication Date
ZA200908303B true ZA200908303B (en) 2012-08-29

Family

ID=38474578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/08303A ZA200908303B (en) 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Country Status (14)

Country Link
US (1) US20100113613A1 (https=)
EP (1) EP1996175A4 (https=)
JP (1) JP2009529502A (https=)
KR (1) KR20090026247A (https=)
CN (1) CN103054837A (https=)
AU (1) AU2007222864A1 (https=)
BR (1) BRPI0708725A2 (https=)
CA (1) CA2644804A1 (https=)
EA (1) EA200801967A1 (https=)
IL (1) IL193970A0 (https=)
MX (1) MX2008011553A (https=)
NZ (1) NZ571181A (https=)
WO (1) WO2007101353A1 (https=)
ZA (1) ZA200908303B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20100292157A1 (en) * 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2014515408A (ja) * 2011-06-03 2014-06-30 エラン ファーマシューティカルズ，リミティド ライアビリティー カンパニー 行動及び精神障害の治療のためのシロ−イノシトール
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
WO2020123449A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
ATE292131T1 (de) * 1992-10-05 2005-04-15 Virginia Tech Intell Prop Zwischenprodukt zur herstellung von d-chiro- inosose und (+)-d-chiro-inositol
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
DE69333071T2 (de) * 1993-04-05 2004-05-06 Aveve N.V. Phytate-Hydrolyse und enzymatische Zusammensetzung für die Hydrolyse von Phytat
CA2168953A1 (en) * 1993-08-11 1995-02-16 Kiyoshi Sato Process for producing d-chiro-inositol
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
WO2001028356A2 (en) * 1999-10-18 2001-04-26 Muscletech Research And Development Inc. Food supplement for increasing lean mass and strength
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
WO2002062385A2 (en) * 2001-02-06 2002-08-15 Qlt, Inc. Method to prevent vision loss
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ATE458042T1 (de) * 2003-10-14 2010-03-15 Hokko Chem Ind Co Verfahren zur herstellung von scyllo-inositol
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法

Also Published As

Publication number Publication date
IL193970A0 (en) 2009-08-03
EP1996175A1 (en) 2008-12-03
MX2008011553A (es) 2008-12-09
US20100113613A1 (en) 2010-05-06
JP2009529502A (ja) 2009-08-20
AU2007222864A8 (en) 2010-06-10
CN103054837A (zh) 2013-04-24
KR20090026247A (ko) 2009-03-12
EA200801967A1 (ru) 2009-04-28
CA2644804A1 (en) 2007-09-13
AU2007222864A1 (en) 2007-09-13
EP1996175A4 (en) 2009-06-10
WO2007101353A1 (en) 2007-09-13
BRPI0708725A2 (pt) 2011-06-07
NZ571181A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
ZA200908303B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
ZA200809528B (en) Treatment for depressive disorders
IL213341A0 (en) Dipeptide linked medicinal agents
IL212404A0 (en) Compounds for treating ophthalmic diseases and disorders
IL194123A0 (en) Methods for reducing protein aggregation
PL2004155T3 (pl) Inhibitory agregacji białek
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
ZA200809527B (en) Treatment for depressive disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
PL2341047T3 (pl) Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie
EP1993523A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
GB0914423D0 (en) Treatment of protein aggregation diseases
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200807993B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
IL212719A0 (en) Gold nanoparticles coated with polyelectrolytes and use thereof as medicament for the treatment of neurodegenerative diseases caused by protein aggregates
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders
GB0616122D0 (en) Formulation for treatment of skin disorders
HK1160633A (en) Compounds for treating ophthalmic diseases and disorders